Share this page
Print this page
Email alert
Calistoga Pharamaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases.
MEDIA COVERAGE
Drug Clinical Trials in Nashville Offer Relief to Leukemia Patients
22 September 2010 | The Tennessean |
30 August 2010 | FierceBiotech |
Calistoga Eying Registration Trials with New Funds
22 July 2010 | EP Vantage |
12 July 2010 | The Huntsville Times |
Calistoga banks $40M Series C for pivotal trial work
30 June 2010 | FierceBiotech |
Calistoga Builds More Momentum for Cancer Drug, Eyes Pivotal Trial Next Year
8 December 2009 | Xconomy |
Calistoga Cancer Drug Shows "Encouraging" Preliminary Results in Small Study
19 October 2009 | Xconomy |
BIO Announces Selection of 2009 Presenting Companies for 8th Annual BIO Investor Forum
1 September 2009 | Biotechnology Industry Organization |
1 August 2009 | Pharmaceutical Executive |
Calistoga Investors Return for $30M Series B
5 May 2009 | FierceBiotech |
Calistoga Reunites Icos Execs To Pursue Cancer, Inflammation Drugs
11 March 2009 | Xconomy |
Calistoga Pharmaceuticals hires first CEO from Atlanta company
9 October 2008 | Seattle Times |
New target promises better asthma and allergy drugs
14 February 2008 | www.reuters.com |
Calistoga wraps up funding at $26 million.
3 January 2008 | blog.seattlepi.nwsource.com |
Calistoga Pharmaceuticals ups financing round by $5M.
2 January 2008 | www.seattle.bizjournals.com |
Calistoga wraps up $21 million financing round.
1 April 2007 | www.drugdiscoverynews.com |
Icos spinoff Calistoga raises $21M.
15 March 2007 | www.seattle.bizjournals.com |
Biotechnology startup rises from Icos ashes, Promising cancer treatment licensed.
15 March 2007 | www.seattlepi.nwsource.com |
ICOS spin-off gets first round and exec team.
15 March 2007 | www.fiercebiotech.com |
